1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Oct 2020
Admin
News Article

Cstone And Legochem Biosciences Enter Global Licensing Agreement For New Antibody Drug Conjugate

Suzhou, China, Oct. 29, 2020 /Prnewswire/ -- Cstone Pharmaceuticals ("Cstone", Hkex: 2616) Announced Today A Licensing Agreement With Legochem Biosciences, Inc. ("Lcb", Kosdaq:141080), For The Development And Commercialization Of Lcb71, A Potential First-In-Class/Best-In-Class Antibody Drug Conjugate ("Adc").Under The Agreement, Cstone Obtains The Exclusive Global Right To Lead Development And Commercialization Of Lcb71 Outside The Republic Of Korea. Lcb Will Receive An Upfront Payment Of Us$10 Million, And Up To Us$353.5 Million In Cumulative Milestone Payments, Plus Tiered Royalties.Frank Jiang, M.D., Ph.D., Chairman And Chief Executive Officer Of Cstone, Said: "We Are Very Pleased To Form This Partnership With Lcb, A Leading Adc Platform Company, To Obtain Global Rights To An Asset With Highly Differentiated Attributes In An Exciting New Field Of Oncology. The Agreement Adds The First Adc To Cstone'S Development Pipeline, And Bolsters Our Precision Medicine Franchise With A New Modality. We Look Forward To Harnessing Its Full Potential And Bringing It To Patients Around The World."Lcb71 Is A Pre-Clinical Adc Entering Into Investigational New Drug ("Ind") Enabling Studies. It Targets Ror1 (Receptor Tyrosine Kinase-Like Orphan Receptor 1), A High-Potential Adc Target For Multiple Solid And Hematological Malignancies. Ror1 Protein Expression Is Prevalent In A Variety Of Cancers Including Various Forms Of Leukemia, Non-Hodgkin Lymphoma, And Breast, Lung, And Ovarian Cancers.Lcb71 Has A Proprietary Tumor-Activated Pyrrolobenzodiazepine ("Pbd") Prodrug Toxin That Addresses The Typical Toxicity Problem Associated With Traditional Pbd Payloads. It Has Demonstrated Complete Tumor Inhibition Across Several Preclinical Cancer Models, Which May Translate Into A Wide Therapeutic Index For A Range Of Solid And Hematologic Malignancies. Additionally, It Utilizes Site-Specific Conjugation For A Precise Drug Antibody Ratio. This Supports Serum Half-Life And Improves Its Pharmacokinetic Profile, And Also Enables Homogeneous Production And Large-Scale Manufacturing.Dr. Yong-Zu Kim, Ceo And President Of Lcb, Said: "We Are Pleased To Have Reached This Agreement With Cstone, Which Has Demonstrated Extensive Oncology Expertise, Especially In Global Clinical Development. This Partnership Puts Lcb71 On A Path To Development And Commercialization For Patients Worldwide. We Are Convinced That Cstone Is The Right Partner To Secure The Future Of This Important Drug."About CstoneCstone Is A Biopharmaceutical Company Focused On Developing And Commercializing Innovative Immuno-Oncology And Precision Medicines To Address The Unmet Medical Needs Of Cancer Patients In China And Worldwide. Established At The End Of 2015, Cstone Has Assembled A World-Class Management Team With Extensive Experience In Innovative Drug Development, Clinical Research, And Commercialization. With A Strategic Emphasis On Immuno-Oncology Combination Therapies, The Company Has Built An Oncology-Focused Pipeline Of 15 Drug Candidates, Including Five Late-Stage Candidates At Pivotal Trials Or Registration Stages. With An Experienced Team, A Rich Pipeline, A Robust Clinical Development-Driven Business Model And Substantial Funding, Cstone'S Vision Is To Become Globally Recognized As A Leading Chinese Biopharmaceutical Company By Bringing Innovative Oncology Therapies To Cancer Patients Worldwide. For More Information About Cstone

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!